Shield Therapeutics Announces Submission of a New Drug Application (NDA) for Feraccru for the treatment of Iron Deficiency

London, UK, 1st October 2018: Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients ’ unmet medical needs, today announces that it has received confirmation...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news